Report Publication Announcement • Nov 27, 2019
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 8985U
Faron Pharmaceuticals Oy
27 November 2019
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron´s financial calendar for 2020
Company announcement, 27 November 2019 at 6.00 pm (EET)
TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN) ("Faron" or the "Company"), the clinical stage biopharmaceutical company, announces the following dates for the Company's financial reporting in 2020:
20 March Financial Statement release for full year 2019
27 March Financial Statements for full year 2019
24 September Half-Year Financial Report for the period 1 January - 30 June 2020
The Annual General Meeting is planned for 13 May 2020. A separate stock exchange notice will be issued by Faron´s Board of Directors to convene the meeting.
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
Panmure Gordon (UK) Limited, Nomad and Broker on AIM
Emma Earl, Freddy Crossley
Phone: +44 (0)20 7886 2500
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen, Jussi Majamaa
Phone: +358 (0)40 555 4727
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
Email: [email protected]
Distribution:
Nasdaq Helsinki Ltd
Key media
About Faron Pharmaceuticals Oy
Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Clevegen®, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen® has potential as a single-agent therapy or in combination with other immune checkpoint molecules or other cancer standard cares. Traumakine®, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine®. Faron is based in Turku, Finland. Further information is available at www.faron.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
NORUBVVRKUAAUAA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.